Published online Sep 14, 2013. doi: 10.3748/wjg.v19.i34.5615
Revised: July 15, 2013
Accepted: July 18, 2013
Published online: September 14, 2013
Colorectal cancer (CRC) is one of the most common malignant diseases worldwide and the prognosis is still poor although much progress has been achieved in recent years. In order to reduce CRC-related deaths, many studies are aimed at identifying novel screening- and prognosis-related biomarkers. MicroRNAs (miRNAs) are a class of 18-27-nucleotide single-stranded RNA molecules that regulate gene expression at the post-transcriptional level. It has been demonstrated that miRNAs regulate a variety of physiological functions, including development, cell differentiation, proliferation, and apoptosis. They play important roles in various physiologic and developmental processes and in the initiation and progression of various human cancers. It has been shown that miRNAs can critically regulate tumor cell gene expression, and evidence suggests that they may function as both oncogenes and tumor suppressor genes. In CRC, miRNAs-21 is one of the most important miRNAs and is rapidly emerging as a novel biomarker in CRC, with good potential as a diagnostic and therapeutic target. In this review, we summarize the latest research findings of the clinicopathological relevance of miRNAs-21 in CRC initiation, development, and progress, highlighting its potential diagnostic, prognostic, and therapeutic application, as well as discussing future prospects.
Core tip: We summarize the latest study findings about microRNA-21 in colorectal cancer through a systematic review of literature. We recommend microRNA-21 as one of the most important microRNAs, which is rapidly emerging as a novel biomarker, with good potential as a diagnostic and therapeutic target.